PMID- 22383666
OWN - NLM
STAT- MEDLINE
DCOM- 20130211
LR  - 20220310
IS  - 1931-3543 (Electronic)
IS  - 0012-3692 (Linking)
VI  - 142
IP  - 5
DP  - 2012 Nov
TI  - Comparison of indacaterol with tiotropium or twice-daily long-acting beta -agonists 
      for stable COPD: a systematic review.
PG  - 1104-1110
LID - S0012-3692(12)60610-2 [pii]
LID - 10.1378/chest.11-2252 [doi]
AB  - BACKGROUND: Bronchodilators are central to the symptomatic management of patients 
      with COPD.Previous data have shown that inhaled indacaterol improved numerous 
      clinical outcomes over placebo. METHODS: This systematic review explored the 
      efficacy and safety of indacaterol in comparison with tiotropium or bid 
      long-acting beta 2 -agonists (TD-LABAs) for treatment of moderate to severe COPD. 
      Randomized controlled trials were identified after a search of different 
      databases of published and unpublished trials. RESULTS: Five trials (5,920 
      participants) were included. Compared with tiotropium, indacaterol showed 
      statistically and clinically significant reductions in the use of rescue 
      medication and dyspnea(43% greater likelihood of achieving a minimal clinically 
      important difference [MCID] in the transitional dyspnea index [TDI]; number 
      needed to treat for benefit [NNTB] 5 10). Additionally,the MCID in health status 
      was more likely to be achieved with indacaterol than with tiotropium (OR = 1.43; 
      95% CI, 1.22-1.68; P = .00001; [NNTB ]= 10). Trough FEV 1 was significantly 
      higher at the end of treatment with indacaterol than with TD-LABAs (80 mL, P = 
      .00001). Similarly, indacaterol signifi cantly improved dyspnea (61% greater 
      likelihood of achieving an MCID in TDI, P = .008) and health status (21% greater 
      likelihood of achieving an MCID in St. George's Respiratory Questionnaire, P 5 
      .04) than TD-LABA. Indacaterol showed similar levels of safety and tolerability 
      to both comparators. CONCLUSIONS: Available evidence suggests that indacaterol 
      may prove useful as an alternative to tiotropium or TD-LABA due to its effects on 
      health status, dyspnea, and pulmonary function.
FAU - Rodrigo, Gustavo J
AU  - Rodrigo GJ
AD  - Departamento de Emergencia, Hospital Central de las Fuerzas Armadas, Montevideo, 
      Uruguay. Electronic address: gustavo.javier.rodrigo@gmail.com.
FAU - Neffen, Hugo
AU  - Neffen H
AD  - Unidad de Medicina Respiratoria, Hospital de Ninos "O. Allassia" Santa Fe, 
      Argentina.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Adrenergic beta-Agonists)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Indans)
RN  - 0 (Quinolones)
RN  - 0 (Scopolamine Derivatives)
RN  - 8OR09251MQ (indacaterol)
RN  - XX112XZP0J (Tiotropium Bromide)
SB  - IM
CIN - Chest. 2012 Nov;142(5):1082-5. PMID: 23131928
MH  - Adrenergic beta-Agonists/*administration & dosage
MH  - Bronchodilator Agents/*administration & dosage
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Indans/*administration & dosage
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology
MH  - Quinolones/*administration & dosage
MH  - Randomized Controlled Trials as Topic
MH  - Respiratory Function Tests
MH  - Scopolamine Derivatives/*administration & dosage
MH  - Tiotropium Bromide
EDAT- 2012/03/03 06:00
MHDA- 2013/02/12 06:00
CRDT- 2012/03/03 06:00
PHST- 2012/03/03 06:00 [entrez]
PHST- 2012/03/03 06:00 [pubmed]
PHST- 2013/02/12 06:00 [medline]
AID - S0012-3692(12)60610-2 [pii]
AID - 10.1378/chest.11-2252 [doi]
PST - ppublish
SO  - Chest. 2012 Nov;142(5):1104-1110. doi: 10.1378/chest.11-2252.